156. Available at: http://www.fda.gov/bbs/topics/NEWS/2004/NEW01008.htm. Accessed February 27, 2004.
157. Available at: http://www.fda.gov/ohrms/ dockets/ac/02/agenda/3882A_Draft.doc. Accessed February 27, 2004.
158. Available at: http://www.fdanews.com/ 1_1/dailynews/7334-1.html. Accessed February 27, 2004.
159. Anand BS, Romero JJ, Sanduja SK, Lichtenberger LM. Phospholipid association reduces the gastric mucosal toxicity of aspirin in human subjects. Am J Gastroenterol. 1999 Jul; 94(7):1818-22.
160. Blakely P, McDonald BR. Acute renal failure due to acetaminophen ingestion: a case report and review of the literature. J Am Soc Nephrol. 1995 Jul;6(1):48-53.
161. Bonkovsky HL, Kane RE, Jones DP, Galinsky RE, Banner B. Acute hepatic and renal toxicity from low doses of acetaminophen in the absence of alcohol abuse or malnutrition: evidence for increased susceptibility to drug toxicity due to cardiopulmonary and renal insufficiency. Hepatology. 1994 May;19(5):1141-8.
162. Clemmesen JO, Ott P, Dalhoff KP, Astrup LB, TageJensen U, Poulsen HE. Recommendations for treatment of paracetamol poisoning. Ugeskr Laegr. 1996 Nov 25; 158(48):6892-5.
163. Conti M, Malandrino S, Magistretti MJ. Protective activity of silipide on liver damage in rodents. Jpn J Pharmacol. 1992 Dec;60(4):315-21.
164. DeLeve LD, Kaplowitz N. Glutathione metabolism and its role in hepatotoxicity. Pharmacol Ther. 1991 Dec;52(3):287-305.
165. Derby LE, Jick H. Acetaminophen and renal and bladder cancer. Epidemiology. 1996 Jul;7(4):358-62.
166. Dunjic BS, Axelson J, Ar扲ajab A, Larsson K, Bengmark S. Gastroprotective capability of exogenous phosphatidylcholine in experimentally induced chronic gastric ulcers in rats. Scand J Gastroenterol. 1993 Jan;28(1):89-94.
167. Gago-Dominguez M., Yuan JM, Castelao JE, Ross RK, Yu MC. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer. 1999 Oct;81(3):542-8.
168. Graudins A, Aaron CK, Linden CH. Overdose of extended-release acetaminophen. N Engl J Med. 1995 Jul 20;333(3):196.
169. Jaeschke H, Werner C, Wendel A. Disposition and hepatoprotection by phosphatidyl choline liposomes in mouse liver. Chem Biol Interact. 1987;64(1-2):127-37.
170. Jones AL. Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. J Toxicol Clin Toxicol. 1998;36(4):277-85.
171. Kaye JA, Myers MW, Jick H. Acetaminophen and the risk of renal and bladder cancer in the general practice research database. Epidemiology. 2001 Nov;12(6):690-4.
172. Kind B, Krahenbuhl S, Wyss PA, Meier-Abt PJ. Clinical-toxicological case (1). Dosage of N-acetylcysteine in acute paracetamol poisoning. Schweiz Rundsch Med Prax. 1996 Aug 2; 85(31-32):935-8.
173. Lieber CS. Role of oxidative stress and antioxidant therapy in alcoholic and non-alcoholic liver diseases. Adv Pharmacol. 1997;38:601-28.
174. Lieber CS. Alcohol: its metabolism and interaction with nutrients. Annu Rev Nutr. 2000;20:395-430.
175. McLaughlin JK, Blot WJ, Mehl ES, Fraumeni JF Jr. Relation of analgesic use to renal cancer: population-based findings. Natl Cancer Inst Monogr. 1985 Dec;69:217-22.
176. Mitchell T, Needham A. Over-the-counter drug is treatment for Alzheimer抯. Life Extension. November, 2000:50-5.
177. Price LM, Poklis A, Johnson DE. Fatal acetaminophen poisoning with evidence of subendocardial necrosis of the heart. J Forensic Sci. 1991 May;36(3):930-5.
178. Richie JP Jr, Lang CA, Chen TS. Acetaminophen-induced depletion of glutathione and cysteine in the aging mouse kidney. Biochem Pharmacol. 1992 Jul 7;44(1):129-35.
179. Siegers CP, Moller-Hartmann W. Cholestyramine as an antidote against paracetamol-induced hepato- and nephrotoxicity in the rat. Toxicol Lett. 1989 May;47(2):179-84.
180. Uhlig S, Wendel A. Glutathione enhancement in various mouse organs and protection by glutathione isopropyl ester against liver injury. Biochem Pharmacol. 1990 Jun 15;39(12):1877-81.
181. Werner C, Wendel A. Hepatic uptake and antihepatotoxic properties of vitamin E and liposomes in the mouse. Chem Biol Interact. 1990;75(1):83-92.
182. Zhao J, Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis. 1999 Nov;20(11):2101-8.
183. Available at: http://www.fda.gov/cder/ drug/analgesics/letter.htm. Accessed February 27, 2004.
184. Available at: http://www.fda.gov/cder/ drug/ analgesics/SciencePaper.htm. Accessed February 27, 2004.
185. Available at: http://www.kidney-cancer-symptoms.com. Accessed February 27, 2004.
186. Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med. 1985 Aug 1;313(5):292-5.
187. Linet MS, Chow WH, McLaughlin JK, et al. Analgesics and cancers of the renal pelvis and ureter. Int J Cancer. 1995 Jul 4;62(1):15-8.
188. McCredie M, Stewart JH, Day NE. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int J Cancer. 1993 Jan 21;53(2):245-9.
189. Brunner FP, Selwood NH. End-stage renal failure due to analgesic nephropathy, its changing pattern and cardiovascular mortality. EDTA-ERA Registry Committee. Nephrol Dial Transplant. 1994;9(10):1371-6.
190. Stewart JH, Hobbs JB, McCredie MR. Morphologic evidence that analgesic-induced kidney pathology contributes to the progression of tumors of the renal pelvis. Cancer. 1999 Oct 15;86(8):1576-82.
191. Dubach UC, Rosner B, Pfister E. Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979). N Engl J Med. 1983 Feb 17;308(7):357-62.
192. Rathbun WB, Killen CE, Holleschau AM, Nagasawa HT. Maintenance of hepatic glutathione homeostasis and prevention of acetaminophen-induced cataract in mice by L-cysteine prodrugs. Biochem Pharmacol. 1996 May 3;51(9):1111-6.
193. Rathbun WB, Holleschau AM, Cohen JF, Nagasawa HT. Prevention of acetamino- phen- and naphthalene-induced cataract and glutathione loss by CySSME. Invest Ophthalmol Vis Sci. 1996 Apr;37(5):923-9.
194. Nagasawa HT, Shoeman DW, Cohen JF, Rathbun WB. Protection against acetamin- ophen-induced hepatotoxicity by L- CySSME and its N-acetyl and ethyl ester derivatives. J Biochem Toxicol. 1996;11(6):289-95.
195. Zhao C, Shichi H. Prevention of acetaminophen-induced cataract by a combination of diallyl disulfide and N-acetylcysteine. J Ocul Pharmacol Ther. 1998 Aug;14(4):345-55.
196. Qian W, Shichi H. Cataract formation by a semiquinone metabolite of acetaminophen in mice: possible involvement of Ca(2+)and calpain activation. Exp Eye Res. 2000 Dec;71(6):567-74.
197. Qian W, Shichi H. Acetaminophen produces cataract in DBA2 mice by Ah receptor-independent induction of CYP1A2. J Ocul Pharmacol Ther. 2000 Aug;16(4):337-44.